FI971026A - Kinoksaliinidioni-NMDA-reseptoriantagonisteja - Google Patents

Kinoksaliinidioni-NMDA-reseptoriantagonisteja Download PDF

Info

Publication number
FI971026A
FI971026A FI971026A FI971026A FI971026A FI 971026 A FI971026 A FI 971026A FI 971026 A FI971026 A FI 971026A FI 971026 A FI971026 A FI 971026A FI 971026 A FI971026 A FI 971026A
Authority
FI
Finland
Prior art keywords
pct
alkyl
group
date mar
ch2ch3
Prior art date
Application number
FI971026A
Other languages
English (en)
Swedish (sv)
Other versions
FI971026A0 (fi
FI113471B (fi
Inventor
Charles Eric Mowbray
Alan Stobie
David John Bull
Christopher Lee Carr
Michael Jonnathan Fray
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of FI971026A0 publication Critical patent/FI971026A0/fi
Publication of FI971026A publication Critical patent/FI971026A/fi
Application granted granted Critical
Publication of FI113471B publication Critical patent/FI113471B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
FI971026A 1994-09-13 1997-03-12 Kinoksaliinidioni-NMDA-reseptoriantagonisteja FI113471B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9418443 1994-09-13
GB9418443A GB9418443D0 (en) 1994-09-13 1994-09-13 Therapeutic agents
PCT/EP1995/003483 WO1996008485A1 (en) 1994-09-13 1995-09-01 Quinoxalinedione nmda receptor antagonists
EP9503483 1995-09-01

Publications (3)

Publication Number Publication Date
FI971026A0 FI971026A0 (fi) 1997-03-12
FI971026A true FI971026A (fi) 1997-03-12
FI113471B FI113471B (fi) 2004-04-30

Family

ID=10761258

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971026A FI113471B (fi) 1994-09-13 1997-03-12 Kinoksaliinidioni-NMDA-reseptoriantagonisteja

Country Status (14)

Country Link
US (1) US5783572A (fi)
EP (1) EP0781279B1 (fi)
JP (1) JP2898097B2 (fi)
AT (1) ATE202099T1 (fi)
CA (1) CA2199845C (fi)
DE (1) DE69521323T2 (fi)
DK (1) DK0781279T3 (fi)
ES (1) ES2158126T3 (fi)
FI (1) FI113471B (fi)
GB (1) GB9418443D0 (fi)
GR (1) GR3036270T3 (fi)
MX (1) MX9701894A (fi)
PT (1) PT781279E (fi)
WO (1) WO1996008485A1 (fi)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874426A (en) * 1995-06-07 1999-02-23 Warner-Lambert Company Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US6110911A (en) * 1995-06-07 2000-08-29 Warner-Lambert Company Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
MY132385A (en) * 1995-08-31 2007-10-31 Novartis Ag 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives
GB9605027D0 (en) 1996-03-09 1996-05-08 Pfizer Ltd Quinoxalinediones
AU5367598A (en) * 1996-11-25 1998-06-22 Warner-Lambert Company Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US6172065B1 (en) 1997-03-04 2001-01-09 Warner-Lambert Company Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US6340758B1 (en) * 1997-05-16 2002-01-22 Warner-Lambert Company Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents
TW403740B (en) 1997-06-10 2000-09-01 Novartis Ag Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide
DE19936521A1 (de) * 1999-08-06 2001-02-15 Gruenenthal Gmbh Substituierte Pyrrolidin-2,3,4-trion-3-oxim-Derivate
AU2002250256B2 (en) * 2001-03-08 2008-04-03 Emory University pH-dependent NMDA receptor antagonists
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
WO2006071274A2 (en) * 2004-12-23 2006-07-06 Voyager Pharmaceutical Corporation Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer’s disease
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
DK2091948T3 (da) 2006-11-30 2012-07-23 Probiodrug Ag Nye inhibitorer af glutaminylcyclase
CA2679446C (en) 2007-03-01 2016-05-17 Probiodrug Ag New use of glutaminyl cyclase inhibitors
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
MX2009014216A (es) * 2007-06-29 2010-07-05 Univ Emory Antagonistas del receptor nmda para neuroproteccion.
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ(qc、ec2.3.2.5)の複素環阻害剤
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
BR112013014484A2 (pt) * 2010-12-13 2016-07-19 Viamet Pharmaceuticals Inc compostos inibidores de metaloenzimas
ES2570167T3 (es) 2011-03-16 2016-05-17 Probiodrug Ag Derivados de benzimidazol como inhibidores de glutaminil ciclasa
DE102015011861B4 (de) 2015-09-10 2018-03-01 Rudolf Schindler Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
GB8827822D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
DK715888D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Quinoxalinforbindelser, deres fremstilling og anvendelse
DE4217952A1 (de) * 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
DE69334237D1 (de) * 1992-06-22 2008-09-25 State Of Oregon Through Oregon Glycinrezeptorantagonisten und ihre verwendung

Also Published As

Publication number Publication date
JP2898097B2 (ja) 1999-05-31
PT781279E (pt) 2001-09-28
GR3036270T3 (en) 2001-10-31
JPH09511523A (ja) 1997-11-18
CA2199845C (en) 2000-08-01
FI971026A0 (fi) 1997-03-12
WO1996008485A1 (en) 1996-03-21
FI113471B (fi) 2004-04-30
ATE202099T1 (de) 2001-06-15
CA2199845A1 (en) 1996-03-21
MX9701894A (es) 1997-06-28
DE69521323D1 (de) 2001-07-19
EP0781279B1 (en) 2001-06-13
GB9418443D0 (en) 1994-11-02
DE69521323T2 (de) 2001-09-20
DK0781279T3 (da) 2001-09-03
US5783572A (en) 1998-07-21
EP0781279A1 (en) 1997-07-02
ES2158126T3 (es) 2001-09-01

Similar Documents

Publication Publication Date Title
FI971026A (fi) Kinoksaliinidioni-NMDA-reseptoriantagonisteja
FI962753A (fi) Menetelmä lääkeaineena käytt¦kelpoisen piperidyyli- tai pyrrolidiinijohdannaisen tai sen farmaseuttisen suolan valmistamiseksi
IL103657A0 (en) Acyclic ethylenediamine derivatives
DE69409525D1 (de) Acetamidderivate und ihre verwendung als modifizierungsmittel des verhaltens der verdauung
NZ508910A (en) Di-substituted piperazine or piperidine derivatives useful as muscarinic antagonists
DE69225500D1 (de) Chinazolinone als mittel gegen angina
PT100620A (pt) Derivados de tetra-hidrocarbazol, seu uso e preparacao e composicoes farmaceuticas que os contem
DE69402981D1 (de) 3,5-dioxo-(2h,4h)-1,2,4-triazine als 5ht1a ligande
ATE297381T1 (de) Ether-muskarinantagonisten
DE69216293D1 (de) 1,4-Disubstituierte Piperidinderivate, ihre Herstellung und therapeutische Verwendung
NZ331060A (en) Quinoxalinediones, preparation and pharmaceutical compositions thereof
NZ331613A (en) Piperazinyl or piperidinyl substituted 1,2,3,4-tetrahydronaphthalene derivatives
SE9703377D0 (sv) New compounds
DK0510003T3 (da) Piperidin-og pyrrolidinderivater
YU140391A (sh) 6-supstituisani-heksahidrobenz (cd)-indoli
ATE144509T1 (de) Imidazolylmethyl-pyridine
ATE214056T1 (de) Benzodiazepinderivate
DK0461012T3 (da) Derivater af ((1-arylpyrrolidin-2-yl)methyl)piperazin, fremstillingen heraf og deres terapeutiske anvendelse

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: PFEIZER IRELAND PHARMACEUTICALS

Free format text: PFEIZER IRELAND PHARMACEUTICALS